DiaMedica Therapeutics Inc. is progressing its recombinant protein therapeutic DM199 through multiple Phase 2 clinical trials targeting severe ischemic conditions including preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS). The latest quarterly filing highlights ongoing enrollment and trial expansions across South Africa, North America, and the UK, supported by FDA Fast Track designation for AIS that could shorten regulatory timelines. With $44.3 million in current assets and a strong liquidity position as of June 2026, DiaMedica is positioned to sustain its R&D efforts through these pivotal clinical milestones. Its proprietary rhKLK1 platform offers a differentiated biologic approach distinct from existing therapies primarily developed in Asia, addressing significant unmet needs in vascular ischemic diseases.